RH1968
This young man, Tye, is very brave. He is a pioneer in the the Calimmune trial. He was treated approximately 7 months ago. He is part of the the first cohort treated with Calimmune's CAL-1 therapy. This means that he did not receive the busulfan pretreatment at all. Calimmune believes that the busulfan pretreatment will prove helpful.
http://clinicaltrials.gov/ct2/show/NCT01734850?term=Calimmune&rank=1
I pray for Tye and all the other people with HIV.
Tye does seem to be doing very well.
Not to sound hypocritical but I intend to make this my last post about Tye unless he officially goes public about the Calimmune trial.
Let's respect his privacy as much as we can now days.
Good luck and GOD bless,
George
This young man, Tye, is very brave. He is a pioneer in the the Calimmune trial. He was treated approximately 7 months ago. He is part of the the first cohort treated with Calimmune's CAL-1 therapy. This means that he did not receive the busulfan pretreatment at all. Calimmune believes that the busulfan pretreatment will prove helpful.
http://clinicaltrials.gov/ct2/show/NCT01734850?term=Calimmune&rank=1
I pray for Tye and all the other people with HIV.
Tye does seem to be doing very well.
Not to sound hypocritical but I intend to make this my last post about Tye unless he officially goes public about the Calimmune trial.
Let's respect his privacy as much as we can now days.
Good luck and GOD bless,
George
Recent BNTC News
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 03/20/2026 08:03:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 01:09:54 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2026 01:07:48 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/11/2026 05:15:29 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/30/2026 09:02:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/03/2025 09:19:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/02/2025 10:27:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2025 10:37:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2025 10:36:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2025 10:35:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:31:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 10:05:33 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/12/2025 11:06:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2025 02:29:10 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/07/2025 02:26:08 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/05/2025 10:17:07 PM
- Benitec Biopharma Shares Surge 20% After FDA Grants Fast Track Status for OPMD Gene Therapy • IH Market News • 11/03/2025 02:35:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2025 12:11:20 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/14/2025 09:00:08 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/14/2025 08:58:35 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/22/2025 09:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2025 08:53:37 PM
